Ποια είναι η τιμή για Brii Biosciences Limited (2137)

Η τιμή για Brii Biosciences Limited (2137) είναι $0.12984512

Ποια είναι η κεφαλαιοποίηση αγοράς για Brii Biosciences Limited (2137)

Η κεφαλαιοποίηση αγοράς για Brii Biosciences Limited (2137) είναι $93.64M

Brii Biosciences Limited (2137) Τιμή και Κεφαλαιοποίηση Αγοράς

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.

Η τιμή για 2137	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$7,226.23 $93.64M	NVDA	$5.211T	+5,565,167.76%
$6,304.64 $93.64M	AAPL	$4.547T	+4,855,410.98%
$5,771.80 $93.64M	GOOG	$4.162T	+4,445,045.56%
$4,981.86 $93.64M	MSFT	$3.593T	+3,836,673.56%
$3,872.65 $93.64M	AMZN	$2.793T	+2,982,414.27%

Η τιμή για 2137

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$7,226.23 $93.64M